Abelacimab Explained

Type:	mab
Mab Type:	mab
Target:	Factor XI and its active form Factor XIa
Dailymedid:	Abelacimab
Licence Us:	Abelacimab
Routes Of Administration:	Intravenous
Legal Status:	Investigational
Cas Number:	1610943-06-0
Chemspiderid:	none
Kegg:	D10821
Synonyms:	MAA868

Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation, under development by Anthos Therapeutics.

Mechanism of action

It is anti-factor XI antibody.^{[1] [2]}

See also

• Antibody
• Monoclonal antibody
• Immunology

Notes and References

1. Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, Raskob GE, Weitz JI . 6 . Abelacimab for Prevention of Venous Thromboembolism . The New England Journal of Medicine . 385 . 7 . 609–617 . August 2021 . 34297496 . 10.1056/NEJMoa2105872 . 236198598 . free .
2. Web site: Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant) . Business Wire . 18 September 2023 .